CancerDrs

Leukemia clinical trials in Arkansas

13 actively recruiting leukemia trials at 5 sites across Arkansas.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting NIH

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in Arkansas:
  • Mercy Hospital Fort Smith — Fort Smith, Arkansas
  • CHI Saint Vincent Cancer Center Hot Springs — Hot Springs, Arkansas
  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs …

Sponsor: Children's Oncology Group
NCT ID: NCT04293562
Sites in Arkansas:
  • Arkansas Children's Hospital — Little Rock, Arkansas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutatio…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06852222
Sites in Arkansas:
  • University of Arkansas at Little Rock — Little Rock, Arkansas
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

This phase III trial compares the effect of xylitol dental wipes to dental wipes without xylitol for the reduction of bloodstream infection in children with acute myeloid leukemia (AML). Xylitol is a naturally occurring sugar compound foun…

Sponsor: Children's Oncology Group
NCT ID: NCT07022678
Sites in Arkansas:
  • Arkansas Children's Hospital — Little Rock, Arkansas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrut…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT05947851
Sites in Arkansas:
  • Highlands Oncology Group ( Site 5405) — Springdale, Arkansas
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myelo…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564390
Sites in Arkansas:
  • University of Arkansas for Medical Sciences — Little Rock, Arkansas
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317649
Sites in Arkansas:
  • University of Arkansas for Medical Sciences — Little Rock, Arkansas
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Arkansas:
  • Arkansas Children's Hospital — Little Rock, Arkansas
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554393
Sites in Arkansas:
  • University of Arkansas for Medical Sciences — Little Rock, Arkansas
View on ClinicalTrials.gov →
NA Recruiting Network

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.

Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT05108298
Sites in Arkansas:
  • Mercy Hospital Fort Smith — Fort Smith, Arkansas
  • CHI Saint Vincent Cancer Center Hot Springs — Hot Springs, Arkansas
  • CARTI Cancer Center — Little Rock, Arkansas
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Arkansas:
  • Massive Bio SYNERGY-AI site — Little Rock, Arkansas
View on ClinicalTrials.gov →
Recruiting Academic/Other

A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab

The goal of this observational study is to establish a clear vaccination protocol for pediatric patients (less than 21 years old) who have received treatment for B-cell Acute Lymphoblastic Leukemia/Lymphoma. The main study aims are: * Eval…

Sponsor: Arkansas Children's Hospital Research Institute
NCT ID: NCT07422337
Sites in Arkansas:
  • Arkansas Children's — Little Rock, Arkansas
  • Arkansas Children's Northwest — Springdale, Arkansas
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-10